Sélectionner la langue
HLA-A*1101 & B2M & KRASG12R (VVVGARGVGK)
HLA-A*1101 & B2M & KRASG12R (VVVGARGVGK) Liste de produits
- Attribut
Protein (1)
- Bibliothèque de produits
En ligne (1)
- Espèces
Human (1)
- Étiquette
His Tag & Avi Tag (1)
- Marqueur
Biotin-labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HLR-H82E2 |  Human | HEK293 | Biotinylated Human HLA-A*11:01&B2M&KRASG12R (VVVGARGVGK) Complex Protein (Monomer, MALS verified) |  |  |  Ajouter au panier |
Quantité totale1
- 1
HLA-A*1101 & B2M & KRASG12R (VVVGARGVGK)Contexte de la molécule
The peptide VVVGARGVGK, derived from the KRAS G12R mutation and presented by the HLA-A*11:01/β2-microglobulin (β2m) complex, is a pivotal antigenic target in antitumor immunity. This complex plays a crucial role by activating specific cytotoxic T lymphocytes (CTLs), enabling the immune system to recognize and eliminate tumor cells harboring the KRAS G12R mutation.
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Alzheimer Disease; Parkinson Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
| Florzolotau (Aprinoia Therapeutics) | [18F]APN-1607; [18F]MNI-958; APN-0000455; F0-PBB3; PM-PBB3; [18F]PM-PBB3; APN-1607; 18F-PM-PBB3; 18F-APN-1607 | Phase 3 Clinical | Aprinoia Therapeutics Ltd | Supranuclear Palsy, Progressive; Nerve Degeneration; Alzheimer Disease; Cognitive Dysfunction; Diagnostic agents; Cognition Disorders | Details |
| E-2814 | E-2814 | Phase 3 Clinical | Eisai Co Ltd | Dementia; Alzheimer Disease | Details |
| Izaflortaucipir F-18 | [18F]PI-2620; PI-2620; 18F-PI-2620 | Phase 3 Clinical | Piramal, Ac Immune Sa | Hypotension; Supranuclear Palsy, Progressive; Brain Concussion; Opioid-Related Disorders; Frontotemporal Lobar Degeneration; Alzheimer Disease; Cognitive Dysfunction | Details |
| Leuco methylthioninium | LMT-X; TRX-0237; Leuco-MTx; LMTM; L-MTx; HMTM | Phase 3 Clinical | Taurx Pharmaceuticals | Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
| XTR-006 | XTR-006 | Phase 3 Clinical | Tauopathies; Alzheimer Disease | Details | |
| Zagotenemab | LY-3303560 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
| Posdinemab | JNJ-63733657; JNJ-3657 | Phase 2 Clinical | Alzheimer Disease; Cognitive Dysfunction; Dementia | Details | |
| [18F]GTP-1 | [18F]GTP-1 | Phase 2 Clinical | Genentech Inc | Alzheimer Disease | Details |
| FluoroTau | [18F]THK-5351; GE-216; F-18-THK-5351 | Phase 2 Clinical | Tohoku University | Kidney Neoplasms; Carcinoma, Renal Cell; Alzheimer Disease; Cognitive Dysfunction; Neurodegenerative Diseases; Diabetes Mellitus | Details |
| [18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
| ISIS-814907 | BIIB-080; ISIS-814907; IONIS-MAPTRx; ISIS-BIIB4Rx; IONIS-BIIB4RX | Phase 2 Clinical | Biogen Inc, Ionis Pharmaceuticals Inc | Cognitive Dysfunction; Dementia; Alzheimer Disease | Details |
| Tilavonemab | C2N-8E12; ABBV-8E12 | Phase 2 Clinical | C2n Diagnostics Llc | Supranuclear Palsy, Progressive; Alzheimer Disease | Details |
| Alzheimer's disease vaccine (Axon Neuroscience) | AADvac-1 | Phase 2 Clinical | Axon Biochemicals | Alzheimer Disease; Primary Progressive Nonfluent Aphasia | Details |
| Semorinemab | MTAU-9937A; MTAU9937A; RG-6100; RO7105705; RO-7105705 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
| APN-1701 | [18F]AM-PBB3; 18F-AM-PBB3; APN-1701 | Phase 2 Clinical | National Institute Of Radiological Sciences, Aprinoia Therapeutics Ltd | Nerve Degeneration; Alzheimer Disease | Details |
| Anti-tau antibody (Prothena) | PRX-005; BMS-986446 | Phase 2 Clinical | Prothena | Alzheimer Disease; Frontotemporal Dementia | Details |
| Bepranemab | UCB-0107 | Phase 2 Clinical | Ucb | Supranuclear Palsy, Progressive; Alzheimer Disease | Details |
| [18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
| PNT-001 | PNT-001 | Phase 1 Clinical | Pinteon Therapeutics Inc | Brain Injuries, Traumatic; Alzheimer Disease | Details |
| ReS19-T | ReS19-T | Phase 1 Clinical | Remynd | Alzheimer Disease | Details |
| Mecripyrine Hydrochloride | SCR-1693; Y-1A; Y-1 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd, NeuroDawn Pharmaceutical Co Ltd | Brain Neoplasms; Alzheimer Disease | Details |
| Lu-AF87908 | Lu-AF87908; Lu-AF-87908 | Phase 1 Clinical | H. Lundbeck A/S | Alzheimer Disease | Details |
| RDC-5 | RDC-5 | Phase 1 Clinical | Amyotrophic Lateral Sclerosis | Details | |
| MC-1 (Lilly) | MC-1 (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
| OLX-07010 | OLX07010 | Phase 1 Clinical | Oligomerix Inc | Supranuclear Palsy, Progressive; Alzheimer Disease; Dementia; Neurodegenerative Diseases | Details |
| Protollin | Phase 1 Clinical | Brigham and Women's Hospital Inc | Alzheimer Disease | Details | |
| ADEL-Y01 | ADEL-Y01 | Phase 1 Clinical | Oscotec Inc, ADEL Inc | Tauopathies; Alzheimer Disease | Details |
| MK-2214 | MK-2214 | Phase 1 Clinical | Merck Sharp & Dohme LLC | Alzheimer Disease | Details |
| APNmAb-005 | APNmAb-005 | Phase 1 Clinical | Aprinoia Therapeutics Ltd | Nerve Degeneration; Alzheimer Disease; Tauopathies | Details |
| NIO-752 | NIO-752 | Phase 1 Clinical | Novartis Pharma Ag | Supranuclear Palsy, Progressive; Cognitive Dysfunction; Alzheimer Disease; Neurodegenerative Diseases | Details |
| BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
| BIIB-076 | NI-105; BIIB-076 | Phase 1 Clinical | Biogen Inc, Neurimmune Ag | Alzheimer Disease | Details |
| 11C-PBB3 | 11C-PBB3 | Clinical | National Institute Of Radiological Sciences | Alzheimer Disease | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Flortaucipir F18 | 18F-AV-1451; T807; F-18-AV-1451 | Approved | Siemens Medical Solution | Tauvid | United States | Alzheimer Disease | Avid Radiopharmaceuticals Inc | 2020-05-28 | Alzheimer Disease; Frontotemporal Dementia; Neurodegenerative Diseases; Cognition Disorders; Corticobasal degeneration; Cognitive Dysfunction; Dementia; Tauopathies; Parkinson Disease; Supranuclear Palsy, Progressive; Pick Disease of the Brain; Chronic Traumatic Encephalopathy; Aphasia, Primary Progressive; Brain Concussion; Brain Injuries, Traumatic; Depression; Brain Injuries | Details |
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :